GCA is a chronic granulomatous vasculitis that affects large-and medium-sized vessels. Both the innate and the adaptive immune system are thought to play an important role in the initial events of the pathogenesis of GCA. Amplification cascades are involved in the subsequent development and progression of the disease, resulting in vascular inflammation, remodelling and occlusion. The development of largevessel vasculitis in genetically modified mice has provided some evidence regarding potential mechanisms that lead to vascular inflammation. However, the participation of specific mechanistic pathways in GCA has not been fully established because of the paucity and limitations of functional models. Treatment of GCA is evolving, and novel therapies are being incorporated into the GCA treatment landscape. In addition, to improve the management of GCA, targeted therapies are providing functional proof of concept of the relevance of particular pathogenic mechanisms in the development of GCA and in sustaining vascular inflammation.
Introduction
GCA is a chronic granulomatous vasculitis with a tropism for large-and medium-sized vessels, particularly the carotid and vertebral arteries [1, 2] . Epidemiological studies report an estimated annual GCA incidence ranging from 1.1 to 32.8 cases per 100 000 individuals aged 550 years; incidence varies according to geographic location [3, 4] . However, GCA patients with disease restricted to the large vessels may not have been identified in these studies because of the absence of systematic, crosssectional imaging modalities. As a result, these epidemiological figures are likely to underestimate the true incidence of GCA.
Histological examination of temporal artery biopsy (TAB) can often be used to identify GCA [5] (Figs 1 and 2 ), given the common involvement of the superficial temporal artery and its ease of access [6, 7] . Although imaging methods are important tools and are widely used for the diagnosis of GCA, abnormal TAB findings provide the best diagnostic specificity [8] , and TAB samples may also provide a valuable source of tissue for investigating the pathogenesis of GCA. To date, our understanding of GCA pathogenesis is largely based on immunopathological and molecular studies performed with TAB samples. However, the majority of these studies are observational in nature, and conclusions are based mainly on the previously known functions of the molecules identified and their correlation with clinical or histological abnormalities.
Functional studies evaluating mechanistic pathways in GCA are scarce.
Advances in the treatment of GCA include testing of new targeted therapies. In addition to broadening the therapeutic armamentarium for this disease, the efficacy or inefficacy of novel therapies provides important functional proof of concept for the specific pathways involved in sustaining vascular inflammation in GCA.
Current understanding of GCA pathogenesis

Predisposing factors
Epidemiological studies report differences in the incidence of GCA among ethnic groups, a higher risk in the ageing population (550 years of age) and a female predominance; this suggests that GCA pathogenesis is driven by multiple factors, including genetic substrate, sex and alterations of the immune and arterial systems related to ageing [4, 9] . However, the role of age and sex in the development of GCA remains elusive.
A genetic component in the pathogenesis of GCA is supported by observations of sporadic family clustering of affected members, along with the predominance of the disease in whites, particularly those from northern Europe or of northern European descent [10, 11] . Indeed, an increased risk of GCA is associated with polymorphisms in a variety of genes that mediate immune, inflammatory and vascular responses [11, 12] .
Candidate gene studies have shown an association between GCA and genetic variants in the MHC region, particularly with class II HLA-DRB1*04 alleles (usually DRB1*0401, but also DRB1*0404) [11, 13] . Recently, large-scale fine mapping of genes related to immune responses confirmed a strong association between variants in the class II MHC region and GCA susceptibility [14] . The amino acids resulting from these risk variants are located in the antigen-binding cavity of HLA molecules. This finding suggests that GCA may be an antigendriven disease, supporting the role of the adaptive immune system in development of the disease.
A recent genome-wide association study has also revealed that, outside the MHC region, variants in genes related to vascular response to inflammation and remodelling, such as plasminogen and prolyl 4-hydroxylase subunit alpha 2, are also associated with GCA risk [15] .
Initial events of GCA
The initial triggering agent(s) in GCA has not been consistently identified. Several pathogens have been proposed as aetiological agents in GCA, but no definitive causal relationship with a particular microorganism or viral agent has been demonstrated [16, 17] , and none of the pathogenic sequences detected in temporal arteries have been unequivocally associated with GCA [18] . However, these
FIG. 1 Histopathological changes induced by GCA in temporal arteries
(A) Normal temporal artery biopsy with clearly defined layers (I: intima; M: media; Ad: adventitia) and a preserved internal elastic lamina (arrowheads). (B) Temporal artery biopsy from a patient with giant cell arteritis highlighting the presence of typical transmural mononuclear infiltration (arrows) with disappearance of the organized medial layer and internal elastic lamina, along with prominent intimal hyperplasia (IH). Arrowheads point to some of the numerous giant-cells.
FIG. 2 Neovessel formation in giant-cell arteritis lesions
Immunofluorescence staining of endothelial cells using an Alexa Fluor 488-conjugated mouse anti-human CD31 mAb (ImmunoTools) (yellow). Nuclei are stained with 4 0 ,6-diamidino-2-phenylindole (blue). A: adventitia; I: intima; L: lumen; M: media.
pathogenic sequences may play a role in the activation of pathogen sensing receptors given that innate immune mechanisms may also contribute to GCA [19] .
Role of the innate immune system
Cells of the innate immune system appear to play a role in the pathogenesis of GCA (Fig. 3A) . Dendritic cells have been detected in normal or early inflamed large and medium-sized arteries [2023] and may play an important role in the pathogenesis of GCA. The maturation of dendritic cells from a non-stimulatory to a T cell activating state in the arterial adventitia is thought to be a critical event in the initiation of GCA [22] . Dendritic cells can be activated via toll-like receptors, resulting in the production of chemokines (e.g. CCL19 and CCL21) that attract and retain additional dendritic cells [22, 23] . In addition, dendritic cells express activation (CD83) and co-stimulatory (CD86) molecules that are responsible for the activation of T cells [21, 22] , which in turn are modulated by immune checkpoints. In GCA, inefficiency of the programmed death 1 (PD-1) receptor/programmed death ligand 1 (PD-L1) immune checkpoint has been observed in GCAaffected temporal arteries; this is thought to contribute to the excessive infiltration of activated T cells into affected medium-and large-sized blood vessels [24] .
Role of the adaptive immune system
Involvement of the adaptive immune system appears to be critical to the initial development of vascular inflammation in GCA-involved vessels (Fig. 3A) . Observed oligoclonal T cell expansion in GCA lesions supports the participation of antigen-specific adaptive immune responses in GCA [25] . Pathogenic pathways mediated by both IFN-g-producing Th1 and IL-17-producing Th17 cells are thought to play a role in the pathogenesis of GCA, contributing to systemic and vascular manifestations of the disease ( Fig. 3A and B) [26] . Consistent with the relevant role of T cells in GCA, DNA methylation analysis of the temporal artery microenvironment in GCA has revealed that genes related to T cell activation and Th1/Th17 differentiation were hypomethylated in GCA lesions [27] . Increased production of the pro-inflammatory cytokine IFN-g has been shown in GCA-involved arteries [28, 29] , resulting in the expression of IFN-g-induced products in lesions, including class II MHC antigens [30] , endothelial adhesion molecules [31] , inducible nitric oxide synthase [32] and chemokines [29, 33, 34] . IFN-g is a potent activator of macrophages, the predominant cell population in GCA lesions, and is thought to drive the granulomatous reaction and transformation of macrophages to giant cells in these lesions [30] . More recent studies also suggest the involvement of Th17-mediated mechanisms in the development of GCA [35, 36] . Th17 cells produce the pro-inflammatory cytokine IL-17A, which has pleiotropic effects on a variety of cells, including macrophages, neutrophils, endothelial cells and fibroblasts, and actively contributes to inflammatory cascades [37] . Th1 and Th17 precursor cells (CD161 + CD4 + T lymphocytes) have been identified in the inflammatory infiltrates of TAB specimens from patients with GCA [38] , and pro-inflammatory cytokines that promote Th17 differentiation have been observed in patients with GCA, including IL-1b, IL-21, TGF-b and IL-6 (Fig. 3C ) [25, 32, 39, 40] . IL-12/23p40 and IL-23p19 subunits are expressed in GCA lesions [35] , and the resulting cytokine, IL-23, is pivotal in maintaining Th17 differentiation. As a result, IL-17A expression is increased in GCA lesions [36] . These elevated levels of IL-17A are rapidly reduced in biopsies obtained from patients with GCA following treatment with glucocorticoids [36] , suggesting that IL-17A suppression may contribute to the dramatic symptomatic improvement in patients with GCA who receive high-dose glucocorticoid therapy. Interestingly, strong expression of IL-17A in the involved arteries of patients with GCA was associated with a better response to glucocorticoid therapy with few relapses [36] . Regulatory T cells, which limit activation of the immune system and the accompanying inflammatory response, are also present in vascular lesions and are decreased in peripheral blood of patients with GCA [36, 38] . Given the well-recognized plasticity of T cell subsets, regulatory T cells may transiently lose their suppressive state and may themselves produce IL-17A in a strongly inflammatory microenvironment with abundant production of cytokines (e.g. GCA lesions) [36] . These abnormalities are reversed in peripheral blood regulatory T cells in patients with GCA treated with the anti-IL-6 receptor mAb, tocilizumab, highlighting the role of IL-6 in promoting a proinflammatory phenotype in regulatory T cells [41] .
Although B cells are not abundant, their presence in GCA lesions has been observed [20, 42, 43] , sometimes forming tertiary lymphoid structures [44] . While GCA has been primarily considered a T cell-mediated disease, it is important to note that B lymphocytes play a crucial role in T cell activation. In patients with active GCA, circulating levels of B cells are decreased, but recover following glucocorticoid treatment and are thought to be recruited into inflamed vessels [42] . In addition, IL-6 production by B cells is enhanced and B cell-activating factor is associated with disease activity in GCA [42, 45] . Additional evidence supporting the involvement of B cells in GCA includes scattered reports of therapeutic benefit following B cell depletion therapy with rituximab in relapsing patients [46, 47] . However, further clinical research to confirm the benefit of B cell-targeted therapy in GCA is currently lacking.
Amplification cascades
Following the initiating events of GCA, amplification cascades play an important role in the development and progression of inflammatory infiltrates, the development of full-blown transmural inflammation, vascular wall injury and remodelling, the pathological substrate of clinical symptoms and complications of GCA [5, 19, 20, 29, 30, 32] . Macrophages play an important role in this process. Both pro-inflammatory (M1-like) and reparative (M2-like) macrophages are abundant in GCA vascular lesions, and appear to promote neovascularization and several mechanisms of arterial wall damage (e.g. reactive oxygen species, matrix metalloproteinase (MMP)-2 production; Fig. 3D ) [32, 39, 4850] .
The production of cytokines by pro-inflammatory macrophages has prominent local and systemic effects, with a potential impact on disease manifestations and outcome in GCA. The intensity of the systemic inflammatory response in GCA correlates with expression of TNF-a, IL-1b, IL-6 and IL-33 ( Fig. 3C) [39, 48] . Moreover, circulating TNF-a and IL-6, along with tissue expression of TNF-a, have been shown to correlate with relapses and disease persistence [39] . Inflammatory loops associated with GCA may be further reinforced by the upregulation of chemokines, endothelial adhesion molecules and colonystimulating factors in lesions, resulting in the continuous recruitment and expansion of additional inflammatory cells [28, 29, 31, 33] . The formation of new vessels in vascular lesions of GCA (Fig. 2) may be promoted by macrophage production of angiogenic factors, such as VEGF, fibroblast growth factor-2 and PDGFs (Fig. 3D) [30, 49, 51] . Acute phase proteins, typically increased in patients with GCA, may also be angiogenic [52, 53] . The expression of endothelial adhesion molecules by neovessels facilitates the recruitment of additional leucocytes [30, 31, 54] . While angiogenesis is an important process in the progression and maintenance of chronic inflammatory diseases, such as GCA, inflammation-induced angiogenic activity may also play a compensatory role for ischaemia at distal sites in patients with GCA, thus protecting against ischaemic complications [55, 56] .
The role of inflammation in arterial damage
Damage of GCA-involved arteries may in part be related to the presence of cytotoxic lymphocytes in advanced lesions, which might contribute to the depletion of vascular smooth muscle cells (VSMCs) [57] . Oxidative damage and vessel wall injury may also arise as a result of reactive oxygen species produced by activated macrophages [32] . The destructive role of proteases in inflamed arteries is evidenced by upregulation of MMPs, MMP-9 and MMP-2, which have elastinolytic activity and are up-regulated in GCA lesions, whereas their natural inhibitors, tissue inhibitor of metalloproteinases (TIMP)-1 and -2, are down-regulated, yielding an increase in proteolytic balance [32, 50] . Indeed, increased MMP-9/MMP-2 proteolytic activity has been observed in GCA lesions and may contribute to the disruption of elastic fibres and abnormal vascular remodelling [50, 58] (Fig. 3D) . Furthermore, the disruption of elastic fibres may favour aortic dilatation, which is an increasingly recognized and delayed complication of GCA [5861].
Vascular remodelling and occlusion
Patients with GCA may experience symptoms of vascular insufficiency and ischaemic complications due to vascular remodelling through intimal hyperplasia and vessel occlusion (Fig. 1B) . Activated macrophages or injured VSMCs produce growth factors that trigger a vascular remodelling process leading to myofibroblast differentiation of VSMCs, migration towards the intimal layer and deposition of extracellular matrix proteins. Several of these factors are expressed in GCA lesions, including PDGFs, TGF-b and ET-1 (Fig. 3D) ; these factors may contribute to vascular remodelling by inducing myofibroblast activation and the production of matrix proteins [25, 6264] . Indeed, blockade of the PDGF receptor by imatinib mesylate or blocking ET-1 receptors results in reduced myointimal cell outgrowth from cultured temporal arteries of patients with GCA [49, 51, 64] . Circulating concentrations of ET-1 are elevated in patients with GCA who have neuro-ophthalmic ischaemic complications, highlighting their potential role in vasospasm or vascular occlusion [63] . The participation of neurotrophins, such as nerve growth factor and brain-derived neurotrophic factor, in the generation of intimal hyperplasia has been proposed given that they are expressed in GCA lesions and promote the proliferation and migration of VSMCs [65] . A number of microRNAs that regulate the functions of VSMCs are up-regulated in GCA lesions, further supporting their involvement in the generation of intimal hyperplasia [66] . Unfortunately, these vascular remodelling factors do not appear to be substantially down-regulated in GCA lesions following glucocorticoid therapy, suggesting that modulation of their potential impact in vessel stenosis and occlusion may require specific therapeutic approaches in large-vessel vasculitis [29, 35] .
Functional models
Several animal models of large-vessel inflammation have been generated and provide important clues about triggers and mechanisms potentially involved in vascular inflammation. IFN-g-deficient mice infected with murine herpesvirus HV68 develop necrotizing large-vessel vasculitis [67, 68] , suggesting that herpesvirus members can induce vascular inflammation. On the other hand, this evidence underlines the protective role of IFN-g in maintaining virus latency and possibly in avoiding excessive vascular destruction [67, 68] . A mouse model of largevessel arteritis demonstrated that mice deficient in the gene encoding the anti-inflammatory cytokine IL-1 receptor antagonist developed lethal arterial inflammation, thus suggesting a role of the IL-1 receptor antagonist in protecting the vessel wall from inflammatory stimuli [69] . Mice deficient in interferon regulatory factor 4 binding protein have increased expression of IL-21 and IL-17A, along with subsequent development of large-vessel vasculitis, which supports the hypothesis that IL-17 is involved in vascular inflammation [70] . Taken together, these models demonstrate that these molecules and their downstream pathways are relevant to vascular inflammation, but do not completely recapitulate the clinical, anatomical and histopathological features of GCA.
Subcutaneous engraftment of GCA-involved temporal artery fragments into mice with severe combined immunodeficiency has been used for functional studies. In this model, T cell depletion with T cell-specific antibodies reduced T cell-dependent cytokines [71] , dendritic cell depletion reduced inflammation in the explant [22] and depletion of tissue-infiltrating macrophages resulted in the production of reactive oxygen species [72] . Blockade of PD-1 has also been shown to exacerbate adoptively transferred vascular inflammation in engrafted normal arteries. Infiltrates are enriched in PD-1 + T cells, with enhanced production of multiple cytokines, including IFN-g, IL-17 and IL-2, in vascular tissue [24] . Temporal artery culture in 3D matrix has been recently introduced to investigate pathogenic pathways. In this model, it has been shown that glucocorticoids decrease production of inflammatory cytokines but do not influence factors involved in vascular remodelling [29] . The induction of a pro-inflammatory phenotype in VSMCs by IFN-g and their active role in recruiting monocytes has been demonstrated in this model [34] . Blocking PDGF receptor signalling with imatinib or endothelin-1 signalling with receptor antagonists has been shown to reduce myointimal cell outgrowth [51, 64] .
These models have provided interesting insight into some relevant mechanisms of vascular inflammation and remodelling. However, they only examine target tissue isolated from a functional immune system to investigate the pathogenesis of vascular inflammation. Moreover, these models only allow assessment of changes in biomarkers given that clinically relevant disease outcomes such as pain, systemic symptoms, ischaemic complications and aortic dilatation cannot be investigated.
Targeted therapies shed light on the pathogenic mechanisms of GCA Even if unsuccessful, research and development of novel targeted therapies provide unique information regarding the participation or irrelevance of specific pathways in disease pathogenesis. For example, investigation of immune checkpoints for cancer immunotherapy has provided interesting lessons. GCA has developed in some patients with malignant melanoma after blocking cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) with ipilimumab [73, 74] , underlining the relevance of T cells and the immunological synapsis in triggering immune activation leading to GCA. Accordingly, abatacept, a recombinant Ig-CTLA-4 molecule, has demonstrated efficacy in maintaining remission in a recent randomized controlled trial [75] . Therapeutic interventions according to pathogenic mechanisms are summarized in Table 1. TNF-a is a potent, multifunctional, pro-inflammatory cytokine that promotes infiltration of leucocytes via the production of chemokines, the induction of adhesion molecule expression (E-selectin, intercellular adhesion molecule 1 and vascular adhesion molecule 1), and the production of MMPs [76] . The gene encoding TNF-a is hypomethylated in GCA lesions where it is highly expressed, and the association between increased expression of TNF-a and persistent disease activity has been observed in various studies [39] , along with the benefit obtained with TNF blockade in other chronic inflammatory or granulomatous diseases. This evidence provided the rationale for conducting clinical trials to investigate TNF inhibition with infliximab, etanercept or adalimumab in GCA. Unfortunately, TNF-a blockade did not provide an advantage over placebo in maintaining remission in newly diagnosed patients [7679] . The disappointing experience with TNF-a blockade underlines the fact that a biomarker of inflammation is not necessarily a therapeutic target and suggests that TNF-a functions may not be essential for the maintenance of vascular inflammation, or can be supplied by redundant pathways.
IL-6 is a multifunctional cytokine secreted by numerous immune cells (e.g. macrophages, neutrophils, dendritic cells) and exerts pleiotropic effects on a variety of cell types [80] . The effects of IL-6 on the immune system include the activation of macrophages and neutrophils, differentiation of Th17 cells, inhibition of the suppressive activity of regulatory T cells, promotion and differentiation of B cells and stimulation of endothelial cells [80] . Furthermore, IL-6 is thought to play an important role in the switch from acute to chronic inflammation [80] . IL-6 transcripts are abundant in GCA lesions but are also present in normal temporal arteries, indicating a potential role in vascular homeostasis [29, 39] . IL-6 expression in lesions is also significantly higher in patients with GCA with a strong systemic inflammatory reaction [39] . Serum IL-6 is elevated in patients with GCA and correlates with disease activity [45, 8183] . Moreover, persistently increased serum IL-6 is found in patients with relapsing disease [84] . Recently, IL-6 receptor blockade with tocilizumab was shown to be superior to placebo in maintaining remission and sparing glucocorticoids in phases 2 and 3 clinical trials, both in newly diagnosed and relapsing patients [85, 86] . These trials indicate that IL-6-dependent inflammatory pathways are highly relevant in maintaining inflammatory activity in GCA. Short-term clinical outcomes seem to be clearly improved by tocilizumab. Tocilizumab strongly inhibits the systemic inflammatory response, which is an important burden in patients with GCA, as well as cranial and polymyalgic clinical symptoms. However, the impact of tocilizumab on vascular inflammation and vascular remodelling, along with their associated vascular complications, needs to be evaluated; this will provide unique insights into pathogenic mechanisms of vascular inflammation and repair.
Conclusions
To date, our understanding of GCA pathogenesis is largely based on evidence from histopathological characteristics, the identification of cell populations and subpopulations in affected vessels or peripheral blood, the expression of activation and differentiation markers by these cells and the production of certain inflammatory molecules in GCA lesions. The role that infiltrating cells and their products play in the development of GCA is primarily based on the assumption of their known biologic functions and correlation with relevant histopathological features (e.g. neovascularization, intimal hyperplasia, giant-cell formation), clinical phenotypes or disease outcomes [19, 30] . Several animal models of large-vessel inflammation have provided evidence regarding potential mechanisms involved in vascular inflammation. However, the pathogenesis of GCA remains incompletely understood because of the scarcity of functional studies demonstrating the involvement of specific pathways.
The recent introduction of targeted therapies into the treatment landscape for GCA may shed light on the participation of specific pathways in pathogenesis of the disease. In particular, research surrounding immune checkpoint inhibition and cytokine blockade (TNF-a and IL-6) has provided important insights into the roles that the immune system and vascular inflammation play in the development of GCA. Future research into current and novel targeted agents is needed to expand our knowledge [30, 32] Contributes to systemic and vascular manifestations of GCA [26] Angiogenesis [49] May contribute to the disruption of elastic fibres and abnormal vascular remodelling [50] Progression and maintenance of inflammation [26, 30] Blocking regarding specific disease pathways involved in GCAassociated vascular inflammation and repair.
